These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28139399)

  • 21. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
    Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
    Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and prognostic value of the
    Yuan Y; Liu Y; Wu Y; Zhang J; Shen C; Zhang F; Wu C; Hu W
    Int J Biol Markers; 2021 Jun; 36(2):33-39. PubMed ID: 34044655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool?
    Rashid S; Singh N; Gupta S; Rashid S; Nalika N; Sachdev V; Bal CS; Datta Gupta S; Chauhan SS; Saraya A
    Pancreas; 2018 Feb; 47(2):227-232. PubMed ID: 29303908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
    Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound.
    Eshleman JR; Norris AL; Sadakari Y; Debeljak M; Borges M; Harrington C; Lin E; Brant A; Barkley T; Almario JA; Topazian M; Farrell J; Syngal S; Lee JH; Yu J; Hruban RH; Kanda M; Canto MI; Goggins M
    Clin Gastroenterol Hepatol; 2015 May; 13(5):963-9.e4. PubMed ID: 25481712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiplex Digital Polymerase Chain Reaction on a Droplet Array SlipChip for Analysis of
    Hu Q; Kanwal F; Lyu W; Zhang J; Liu X; Qin K; Shen F
    ACS Sens; 2023 Jan; 8(1):114-121. PubMed ID: 36520653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
    Nakano Y; Kitago M; Matsuda S; Nakamura Y; Fujita Y; Imai S; Shinoda M; Yagi H; Abe Y; Hibi T; Fujii-Nishimura Y; Takeuchi A; Endo Y; Itano O; Kitagawa Y
    Br J Cancer; 2018 Mar; 118(5):662-669. PubMed ID: 29360815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic carcinosarcoma with the same KRAS gene mutation in both carcinomatous and sarcomatous components: molecular evidence for monoclonal origin of the tumour.
    Bai Q; Zhang X; Zhu X; Wang L; Huang D; Cai X; Zhou X; Wang J; Sheng W
    Histopathology; 2016 Sep; 69(3):393-405. PubMed ID: 27307095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.
    Li Y; Monzo M; Moreno I; Martinez-Rodenas F; Hernandez R; Castellano JJ; Canals J; Han B; Muñoz C; Navarro A
    Int J Colorectal Dis; 2020 May; 35(5):805-813. PubMed ID: 32088737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
    Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ
    Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer.
    Jun E; Koo B; Kim EJ; Hwang DW; Lee JH; Song KB; Lee W; Park Y; Hong S; Shin Y; Kim SC
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.
    Kuo YB; Chen JS; Fan CW; Li YS; Chan EC
    Clin Chim Acta; 2014 Jun; 433():284-9. PubMed ID: 24685572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.
    Bournet B; Muscari F; Buscail C; Assenat E; Barthet M; Hammel P; Selves J; Guimbaud R; Cordelier P; Buscail L
    Clin Transl Gastroenterol; 2016 Mar; 7(3):e157. PubMed ID: 27010960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
    Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE
    Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
    Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
    Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly specific detection of KRAS single nucleotide polymorphism by asymmetric PCR/SERS assay.
    Lyu N; Rajendran VK; Li J; Engel A; Molloy MP; Wang Y
    Analyst; 2021 Sep; 146(18):5714-5721. PubMed ID: 34515700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.